Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy

Effects of ranolazine on the arrhythmic substrate in hypertrophic cardiomyopathy

<p><strong>Introduction:</strong> Hypertrophic cardiomyopathy (HCM) is a leading cause of lethal arrhythmias in the young. Although the arrhythmic substrate has been hypothesised to be amenable to late Na+ block with ranolazine, the specific mechanisms are not fully understood. The...

Bibliografski detalji
Glavni autori:	Coleman, JA, Doste, R, Beltrami, M, Argirò, A, Coppini, R, Olivotto, I, Raman, B, Bueno Orovio, A
Format:	Journal article
Jezik:	English
Izdano:	Frontiers Media 2024

Slični predmeti

Remodelling of potassium currents underlies arrhythmic action potential prolongation under beta-adrenergic stimulation in hypertrophic cardiomyopathy
od: Doste, R, i dr.
Izdano: (2022)

Electrophysiological mechanisms underlying T wave pseudonormalisation on stress ECGs in hypertrophic cardiomyopathy
od: Coleman, J, i dr.
Izdano: (2023)

Pharmacological management of hypertrophic cardiomyopathy: From bench to bedside
od: Palandri, C, i dr.
Izdano: (2022)

Mechanisms of pro-arrhythmic abnormalities in ventricular repolarisation and anti-arrhythmic therapies in human hypertrophic cardiomyopathy.
od: Passini, E, i dr.
Izdano: (2015)

Mechanisms of ischaemia-induced arrhythmias in hypertrophic cardiomyopathy: a large-scale computational study
od: Coleman, JA, i dr.
Izdano: (2024)

The arrhythmic substrate of hypertrophic cardiomyopathy using ECG imaging
od: Chow, J, i dr.
Izdano: (2024)

Mechanisms and prognostic impact of myocardial ischaemia in hypertrophic cardiomyopathy
od: Coleman, JA, i dr.
Izdano: (2023)

Investigations of electrophysiological mechanisms related to myocardial ischaemia in hypertrophic cardiomyopathy: implications for arrhythmic risk, ECG diagnosis, and antiarrhythmic therapy
od: Coleman, JA
Izdano: (2024)

Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: a Translational Study
od: Coppini, R, i dr.
Izdano: (2019)

Mechanism based therapies enable personalised treatment of hypertrophic cardiomyopathy
od: Margara, F, i dr.
Izdano: (2022)

Distinct ECG phenotypes identified in hypertrophic cardiomyopathy using machine learning associate with arrhythmic risk markers
od: Lyon, A, i dr.
Izdano: (2018)

Files associated with: "Investigations of electrophysiological mechanisms related to myocardial ischaemia in hypertrophic cardiomyopathy: implications for arrhythmic risk, ECG diagnosis, and antiarrhythmic therapy"
od: Coleman, J
Izdano: (2024)

Is DNA testing for hypertrophic cardiomyopathy cost-effective?
od: Wordsworth, S, i dr.
Izdano: (2006)

Sudden death in hypertrophic cardiomyopathy.
od: Watkins, H
Izdano: (2000)

Myocardial dysfunction in hypertrophic cardiomyopathy.
od: Ashrafian, H, i dr.
Izdano: (2001)

The genetic architecture of hypertrophic cardiomyopathy
od: Harper, AR
Izdano: (2020)

Improving the clinical understanding of hypertrophic cardiomyopathy by combining patient data, machine learning and computer simulations: A case study
od: Lyon, A, i dr.
Izdano: (2019)

Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy.
od: Edwards, R, i dr.
Izdano: (1970)

EFFECTS OF PROPRANOLOL ON RESPONSE TO EXERCISE IN HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY
od: Edwards, R, i dr.
Izdano: (1970)

Hypertrophic cardiomyopathy in Noonan Syndrome closely mimics familial hypertrophic cardiomyopathy due to sarcomeric mutations.
od: Hudsmith, L, i dr.
Izdano: (2006)

Cardiac Steatosis Detected in Hypertrophic Cardiomyopathy, Dilated Cardiomyopathy and Aortic Stenosis
od: Suttie, J, i dr.
Izdano: (2011)

Metabolic perturbations in the pathogenesis of hypertrophic cardiomyopathy
od: Ashrafian, H, i dr.
Izdano: (2005)

Linked genetic modifiers in hypertrophic cardiomyopathy
od: Ektisham, J, i dr.
Izdano: (2004)

The genetics of hypertrophic cardiomyopathy: Teare redux.
od: Watkins, H, i dr.
Izdano: (2008)

Correlates of myocardial fibrosis in hypertrophic cardiomyopathy
od: Kramer, CM, i dr.
Izdano: (2018)

Insights into mechanisms and clinical implications of myocardial fibrosis and its progression in hypertrophic cardiomyopathy
od: Raman, B
Izdano: (2019)

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model
od: Wordsworth, S, i dr.
Izdano: (2010)

DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model.
od: Wordsworth, S, i dr.
Izdano: (2010)

Identification of myocardial disarray in patients with hypertrophic cardiomyopathy and ventricular arrhythmias
od: Ariga, R, i dr.
Izdano: (2019)

Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications
od: Raman, B, i dr.
Izdano: (2018)

Diffusion tensor magnetic resonance imaging of myocardial disarray in hypertrophic cardiomyopathy
od: Ariga, R, i dr.
Izdano: (2018)

Metabolomics in hypertrophic cardiomyopathy and other myocardial diseases
od: Pal, N
Izdano: (2015)

Electrocardiogram phenotypes in hypertrophic cardiomyopathy caused by distinct mechanisms: apico-basal repolarization gradients vs. Purkinje-myocardial coupling abnormalities
od: Lyon, A, i dr.
Izdano: (2018)

Paradoxical prolongation of QT interval during exercise in patients with HCM: Cellular mechanisms and implications for diastolic function
od: Coppini, R, i dr.
Izdano: (2022)

Mouse Model of Familial Hypertrophic Cardiomyopathy with E99K ACTC Mutation Recapitulates Many Features of Hypertrophic Cardiomyopathy in Patients
od: Song, W, i dr.
Izdano: (2008)

Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin
od: Toepfer, C, i dr.
Izdano: (2019)

Computational probabilistic quantification of pro-arrhythmic risk from scar and left-to-right heterogeneity in the human ventricles
od: Wallman, M, i dr.
Izdano: (2013)

Multiscale modelling of β-adrenergic stimulation in cardiac electromechanical function
od: Doste, R, i dr.
Izdano: (2021)

Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry
od: Neubauer, S, i dr.
Izdano: (2019)

Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion.
od: Ashrafian, H, i dr.
Izdano: (2003)